Clear All
12250 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
51991-0342-01 51991-0342 Pomalidomide Pomalidomide 1.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Feb 28, 2026 In Use
51991-0343-01 51991-0343 Pomalidomide Pomalidomide 2.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Feb 28, 2026 In Use
51991-0344-21 51991-0344 Pomalidomide Pomalidomide 3.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Feb 28, 2026 In Use
51991-0342-21 51991-0342 Pomalidomide Pomalidomide 1.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Feb 28, 2026 In Use
51991-0346-21 51991-0346 Pomalidomide Pomalidomide 4.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Feb 28, 2026 In Use
51991-0344-01 51991-0344 Pomalidomide Pomalidomide 3.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Feb 28, 2026 In Use
51991-0343-21 51991-0343 Pomalidomide Pomalidomide 2.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Feb 28, 2026 In Use
51991-0346-01 51991-0346 Pomalidomide Pomalidomide 4.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Feb 28, 2026 In Use
66993-0297-02 66993-0297 estrogens, conjugated Conjugated Estrogens 0.625 mg/1 Hormonal Therapy Estrogen Oral Feb 27, 2026 In Use
66993-0298-02 66993-0298 Estrogens, conjugated Conjugated Estrogens 0.9 mg/1 Hormonal Therapy Estrogen Oral Feb 27, 2026 In Use
66993-0299-02 66993-0299 Estrogens, conjugated Conjugated Estrogens 1.25 mg/1 Hormonal Therapy Estrogen Oral Feb 27, 2026 In Use
66993-0295-02 66993-0295 Estrogens, conjugated Conjugated Estrogens 0.3 mg/1 Hormonal Therapy Estrogen Oral Feb 27, 2026 In Use
66993-0296-02 66993-0296 Estrogens, conjugated Conjugated Estrogens 0.45 mg/1 Hormonal Therapy Estrogen Oral Feb 27, 2026 In Use
70518-4293-05 70518-4293 PREDNISONE Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Feb 17, 2026 In Use
70518-4293-06 70518-4293 PREDNISONE Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Feb 17, 2026 In Use
57894-0522-01 57894-0522 AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT) Rybrevant Faspro 3520.0 mg/22mL, 44000.0 mg/22mL Immunotherapy Bispecific Antibody EGFR, MET Subcutaneous Feb 13, 2026 In Use
57894-0515-01 57894-0515 AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT) Rybrevant Faspro 2400.0 mg/15mL, 30000.0 mg/15mL Immunotherapy Bispecific Antibody EGFR, MET Subcutaneous Feb 13, 2026 In Use
83831-0144-05 83831-0144 Etoposide Avopef 100.0 mg/5mL Chemotherapy Plant Alkaloid Epipodophyllotoxins Intravenous Feb 13, 2026 In Use
42708-0195-10 42708-0195 PREDNISONE PREDNISONE 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Feb 13, 2026 In Use
85776-0202-30 85776-0202 Dronabinol DRONABINOL 5.0 mg/mL Ancillary Therapy Antiemetic CB1/CB2 Oral Feb 11, 2026 In Use
69097-0430-96 69097-0430 Filgrastim-txid NYPOZI 300.0 ug/300ug Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Feb 11, 2026 In Use
69097-0429-67 69097-0429 Filgrastim-txid NYPOZI 480.0 ug/480ug Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Feb 11, 2026 In Use
69097-0430-67 69097-0430 Filgrastim-txid NYPOZI 300.0 ug/300ug Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Feb 11, 2026 In Use
69097-0429-96 69097-0429 Filgrastim-txid NYPOZI 480.0 ug/480ug Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Feb 11, 2026 In Use
70518-4524-04 70518-4524 Prednisolone Sodium Phosphate Prednisolone Sodium Phosphate 15.0 mg/5mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Feb 9, 2026 In Use

Found 12250 results — Export these results